[Action of a respiratory stimulant (S 2620), orally administered, in obstructive bronchopulmonary disease (Statistical study) (author's transl)].
D000284:Administration, Oral; D000368:Aged; D001784:Blood Gas Analysis; D001996:Bronchopneumonia / Q000188:drug therapy; D002245:Carbon Dioxide; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010100:Oxygen; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D012119:Respiration / Q000187:drug effects; D012131:Respiratory Insufficiency / Q000188:drug therapy*; D013268:Stimulation, Chemical; D014227:Triazines / Q000627:therapeutic use*
D000697:Central Nervous System Stimulants; D010879:Piperazines; D010919:Placebos; D014227:Triazines; D002245:Carbon Dioxide; D010100:Oxygen
Action d'un stimulant ventilatoire (S 2620), administré oralement, dans les bronchopneumopathies obstructives (Etude statistique)